因塞特医疗（Incyte）近日宣布，其创新药物Zynyz®（Retifanlimab）已获得欧盟委员会批准，可作为晚期肛管鳞状细胞癌（SCAC）的一线治疗方案。这一批准标志着该免疫疗法正式进入欧洲市场，为患者提供了新的治疗选择。
因塞特医疗（Incyte）近日宣布，其创新药物Zynyz®（Retifanlimab）已获得欧盟委员会批准，可作为晚期肛管鳞状细胞癌（SCAC）的一线治疗方案。这一批准标志着该免疫疗法正式进入欧洲市场，为患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.